The study examines how a new oral medication, BI 3000202, behaves in the bodies of healthy adult men. No specific disease is being treated; participants are volunteers without a related medical condition.

The purpose is to evaluate safety, tolerability, and the way the drug moves through the body (pharmacokinetics) at increasing dose levels, and to compare the amount of drug that reaches the bloodstream when taken with food versus on an empty stomach (bioavailability). Participants receive a single dose of either the study drug at one of several strengths (3 mg, 10 mg, 25 mg, or 250 mg) or a placebo in a blinded fashion, followed by blood sampling over 24 hours. In a separate part, the same participants take the drug as a tablet once with a standard meal and once without food, and blood is drawn to measure the drug concentration.

Safety checks include monitoring for any side effects that may be related to the medication, and blood tests are used to calculate measures such as the AUC (total exposure of the drug in the blood) and the highest concentration reached. The study lasts for a short period after each dose, with participants returning for follow‑up visits as needed.